Trump’s New EU Tariff Threat Creates Another Planning Problem for CEOs

European executives making decisions about U.S. manufacturing, sourcing and capital deployment have another variable to consider.

On September 17, 2026, President Donald Trump threatened heavier tariffs on Europe if the European Union moves ahead with a proposal to create a closer relationship with Canada. Canadian Prime Minister Mark Carney has called for deeper cooperation with Europe in areas including trade, technology, energy and critical minerals. Reuters Financial Times

The proposed EU–Canada relationship is not fully defined, and there is no new tariff schedule to model today. Companies should not redesign their businesses around every political statement.

They also cannot ignore the possibility that trade conditions between the United States, Europe and Canada could become less predictable. That uncertainty is the real issue.

For a European company considering a U.S. facility, a major sourcing decision or a new market entry, the question is simple:

Which assumptions become expensive if they are wrong?

That is where management should focus. A company should understand how different tariff scenarios could affect the economics of a new investment, where its supply chain is most exposed, which decisions can wait and where flexibility should be preserved. The best response is not panic. It is scenario planning.

The Canada–EU relationship matters even before the details are settled

The EU’s proposal is broader than a conventional trade discussion. The emerging relationship could involve cooperation in technology, healthcare, energy, security, critical minerals, digital trade, research and other strategic areas.

For companies, that may create opportunities as well as risks. Closer Canada–EU cooperation could lead to new partnerships, sourcing options and investment relationships, particularly in healthcare, technology, advanced manufacturing and critical materials.

At the same time, a stronger Canada–EU relationship could produce new questions for businesses that operate across all three markets. Which rules will apply? Will supply chains become more diversified or more complicated? Could political retaliation affect investment decisions, customs treatment or market access?

Those questions require companies to understand the actual structure of their operations and the assumptions behind major commitments.

The business consequence matters more than the political prediction

CEOs do not need to predict whether Canada ultimately receives a new relationship with the EU or whether Washington follows through on additional tariffs.

They need to know what each plausible outcome could mean for the business.

That means identifying exposure across manufacturing, sourcing, logistics, contracts, data, financing, regulatory approvals and customer commitments.

It also means separating decisions that require action now from decisions that should remain flexible until more is known. Political signals can change quickly. Factories, contracts, supply chains and capital commitments cannot.

What executives should review now

Leadership teams should begin by mapping which products, services and investments depend on the United States, Europe or Canada. They should identify where goods cross borders, where important inputs originate and which contracts assume stable tariff or regulatory conditions.

They should also test whether a proposed investment still makes sense under several scenarios. A project that works under current assumptions may look different if tariffs increase, customs treatment changes or a company loses access to a preferred supplier.

The exercise does not require predicting the future. It just simply requires understanding the cost of being incorrect.

Companies should also review whether their contracts address tariff changes, regulatory shifts, supply interruptions, delays, force majeure, price adjustments and termination rights. These provisions may become more important as trade policy becomes less predictable.

A planning problem, not a reason to freeze

Uncertainty can cause companies to delay decisions unnecessarily. That can be just as costly as moving too quickly.

The goal is not to stop investing, entering markets or building relationships. The goal is to understand which decisions are durable, which can be staged and which should preserve room to adapt.

A company may decide to proceed with a facility but phase the investment. It may retain more than one supplier. It may structure a contract with clearer adjustment mechanisms. It may test a market before making a larger commitment. Those are practical and measured responses to uncertainty.

The lesson for CEOs

The current dispute over Canada, the European Union and possible U.S. tariffs is part of a larger change in the business environment. Executives are planning around movement, not around a stable set of trade and regulatory assumptions.

The practical lesson is straightforward: separate the headline from the business consequence.

Understand where the exposure sits. Test the assumptions behind major decisions. Review the contracts that support those decisions. Preserve enough flexibility to move if the policy environment changes.

Lanton Strategies International works with executives and organizations on policy, market access, government affairs and strategic issues affecting investment, commercialization and growth across the United States and Europe. We help leadership teams understand what policy developments mean for their business and determine practical next steps.

For legal and regulatory matters, Lanton, Lanton & Sosa Law PLLC advises companies on issues affecting healthcare, life sciences, technology, commercialization and business strategy.

This article is provided for informational and educational purposes only and should not be relied upon as legal, investment or other professional advice. Reading it does not create an attorney-client relationship.

When Drug Pricing Policy Starts to Shape Where Medicines Are Made

For years, European pharmaceutical companies have treated manufacturing location as an operational decision. That is changing.

Ipsen is reportedly considering a U.S. manufacturing site while continuing to expand production in the United Kingdom. The company has not made a final decision, but the question itself reflects a broader shift facing European drugmakers. The Wall Street Journal, September 11, 2026

A company deciding where to manufacture a medicine now has to consider more than labor, capacity and logistics. It must also think about tariffs, domestic-production incentives, political pressure, reimbursement rules and the order in which products should be launched in different markets.

A U.S. facility may help a company respond to trade demands or qualify for incentives. It may also bring higher construction and operating costs. Building in Europe may preserve existing expertise and infrastructure, while exposing the company to a different set of political and commercial risks.

The decision becomes even more complicated when a product is approaching launch. A company may have to determine whether the economics justify a new facility, a contract manufacturing arrangement, an acquisition or an expansion of an existing site. Each option affects capital allocation, regulatory planning and the timing of market entry.

This is not only a question for the largest pharmaceutical companies. Smaller biotechs and specialty manufacturers may face the same choice earlier in their development cycle because investors and strategic partners want to know where production will occur and how resilient the supply chain will be.

The larger point is that drug pricing policy is beginning to influence industrial policy. Decisions about reimbursement and market access can affect where companies build, where they hire and where they place their next dollar of investment.

For European life-sciences companies looking toward the United States, manufacturing strategy can no longer be separated from policy strategy.